Lantheus Holdings Inc. is adding to its portfolio yet again, acquiring a clinical-stage radiopharmaceutical company in a deal ...

Lantheus Holdings Inc., a radiopharmaceutical-focused company, has agreed to acquire Evergreen Theragnostics Inc., in an ...

CEO Brian Markison highlighted the acquisition’s alignment with Lantheus' growth strategy, emphasizing its potential to improve patient outcomes and deliver shareholder value. Besides going to a ...

The deal includes an upfront payment of $250m, with the potential for an additional $752.5m in milestone payments.

Lantheus CEO Brian Markison said the company was pleased to increase its holding in Radiopharm, while continuing to work jointly in Australia on the clinical development of radiopharmaceutical assets.

On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Lantheus’ CEO Brian Markison said: “With Evergreen’s manufacturing and development capabilities, we become fully integrated and will ultimately make a difference in the lives of more patients." ...